Despite the wave of criticism that has followed the U.S. Food and Drug Administration’s emergency approval of convalescent plasma to treat COVID-19 patients, infectious disease experts say the therapy remains promising. Some scientists have questioned both the timing of the approval and the veracity of a key survival statistic cited by FDA Commissioner Dr. Stephen Hahn. And the clinical trials needed to make sure that convalescent plasma really works are not yet complete. Still, survivors’ plasma has been on the list of potential COVID-19 treatments since the pandemic began and an emergency approval for its widespread use was not unexpected, said Dr. Liise-anne Pirofski, chair of biomedical research at the Albert Einstein College of Medicine and Montefiore Medical Center, in New York City. Data coming in from around the world shows that antibody-loaded plasma taken from COVID-19 survivors can help people fighting off an infection, Pirofski said. For example, reports from China have shown that desperately ill patients treated late in their disease with convalescent plasma experienced a very rapid decrease in their viral load, Pirofski noted. There’s also no evidence that convalescent plasma can hurt a person, she added. “I cannot think of one shred of data that I have seen that would suggest harm,” Pirofski said. But scientists still don’t know exactly how effective plasma can be, when it would be best administered… read on >

















